Toll Free: 1-888-928-9744

MediGene AG - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 39 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

MediGene AG - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'MediGene AG - Product Pipeline Review - 2014', provides an overview of the MediGene AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of MediGene AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of MediGene AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of MediGene AG's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the MediGene AG's pipeline products

Reasons to buy

- Evaluate MediGene AG's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of MediGene AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the MediGene AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of MediGene AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of MediGene AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of MediGene AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
MediGene AG Snapshot 5
MediGene AG Overview 5
Key Information 5
Key Facts 5
MediGene AG - Research and Development Overview 6
Key Therapeutic Areas 6
MediGene AG - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
MediGene AG - Pipeline Products Glance 11
MediGene AG - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
MediGene AG - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
MediGene AG - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
MediGene AG - Drug Profiles 15
paclitaxel lipsomal 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
sinecatechins 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Dendritic Cell Vaccine for Prostate Cancer 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
RhuDex 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Dendritic Cell Vaccine For Acute Myeloid Leukemia (AML) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
AAVLP Program 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Adoptive T Cell Therapy for Cancer 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Anti-TCR Monoclonal Antibodies for Leukemia and Autoimmune Disease 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
MediGene AG - Pipeline Analysis 25
MediGene AG - Pipeline Products by Target 25
MediGene AG - Pipeline Products by Route of Administration 26
MediGene AG - Pipeline Products by Molecule Type 27
MediGene AG - Pipeline Products by Mechanism of Action 28
MediGene AG - Recent Pipeline Updates 29
MediGene AG - Dormant Projects 33
MediGene AG - Discontinued Pipeline Products 34
Discontinued Pipeline Product Profiles 34
etomoxir 34
G-207 34
L1 Monoclonal Antibody 34
MediGene AG - Company Statement 35
MediGene AG - Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39
List of Tables
MediGene AG, Key Information 5
MediGene AG, Key Facts 5
MediGene AG - Pipeline by Indication, 2014 8
MediGene AG - Pipeline by Stage of Development, 2014 9
MediGene AG - Monotherapy Products in Pipeline, 2014 10
MediGene AG - Phase III, 2014 11
MediGene AG - Phase II, 2014 12
MediGene AG - Phase I, 2014 13
MediGene AG - Preclinical, 2014 14
MediGene AG - Pipeline by Target, 2014 25
MediGene AG - Pipeline by Route of Administration, 2014 26
MediGene AG - Pipeline by Molecule Type, 2014 27
MediGene AG - Pipeline Products by Mechanism of Action, 2014 28
MediGene AG - Recent Pipeline Updates, 2014 29
MediGene AG - Dormant Developmental Projects,2014 33
MediGene AG - Discontinued Pipeline Products, 2014 34
MediGene AG, Subsidiaries 37 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify